Camber Pharmaceuticals has launched Buprenorphine and Naloxone Sublingual Tablets [BUE-pre-NOR-feen and nal-OX-one suhb-ling-gwl], generic for […]
Buprenorphine and Naloxone Sublingual Tablets Added to Portfolio
Currently browsing: News
New to Camber’s Portfolio: Losartan Potassium and Hydrochlorothiazide Tablets
Camber Pharmaceuticals has launched Losartan Potassium and Hydrochlorothiazide Tablets [loe-SAR-tan poe-TAS-ee-um and hye-droe-klor-oh-THYE-a-zide], generic for […]
NACDS TSE 2026 Event Recap
NACDS TSE 2026 in Boston was nothing short of amazing! From connecting with customers and […]
Camber Specialty Marks First Day 1 Injectable Launch
Camber Specialty, a division of Camber Pharmaceuticals, has launched Sugammadex Injection [soo-GAM-ma-dex], its first Day […]
New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
According to the CDC, about 40-45% of adults in the U.S. have hypertension. Indicated for […]
Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
Camber Pharmaceuticals is proud to have been named a Second Merit Finalist for the 2026 […]
Camber Launches Nitazoxanide Tablets
Giardia and Cryptosporidium infections affect an estimated 2 million people annually in the United States, […]
Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio
Camber expands its portfolio with Cisatracurium Besylate Injection, USP [sis-AT-ra-KURE-ee-um], generic to Nimbex®, broadening access […]
Camber Welcomes Summer 2026 Intern Class
Pictured above (left to right): Frank Woodward, Avyan Illapakurthy, Matthew Oliveras, Ella Burgio, Shreya Domakonda, […]
Camber Launches 5 Generics in May
In May 2026, Camber Pharmaceuticals strengthened its portfolio with the launch of five new generic […]